Porton Pharma Solutions and Dragon Sail Pharmaceutical (Shanghai) have signed a strategic cooperation agreement in Guilin, southern of China. This collaboration aims to carry out in-depth cooperation in the research, development, production, and supply chain integration of antibody-drug conjugates (ADC). 

As a leading end-to-end integrated contract development and manufacturing organisation (CDMO), Porton Pharma Solutions boasts globally advanced technology platforms and extensive project delivery experience in small molecules, peptides and oligonucleotides, ADCs (including antibodies, payload-linkers, conjugation, and drug product filling), and Advanced Therapy Medicinal Products.

Dragon Sail Pharmaceutical, on the other hand, has unique advantages in the development of biological drugs such as monoclonal antibodies, bispecific antibodies, and fusion proteins.

By integrating resources, technical capabilities, and production capacities in the ADC drug field, the two companies will leverage supply chain resource sharing and complementary strengths to form a close cooperation mechanism.

This partnership aims to establish a comprehensive one-stop service platform for ADC drugs, encompassing the entire process from bulk drug substances to finished products, from early-stage development to commercial production. By doing so, the collaboration seeks to shorten ADC drug development timelines, enhance service and delivery capabilities, and improve market competitiveness, providing global customers with more efficient and reliable one-stop CMC solutions for ADC drugs.